Karyopharm Therapeutics Inc. (KPTI)

Karyopharm Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	31.39	53.19	136.89	197.45	89.12	130.69
Short-Term Investments	117.95	139.21	142.78	38.16	163.32	133.1
Cash & Cash Equivalents	149.34	192.4	279.66	235.6	252.44	263.79
Cash Growth	-42.97%	-31.20%	18.70%	-6.67%	-4.30%	-19.80%
Receivables	31.08	26.96	47.09	22.5	12.88	7.86
Inventory	2.77	3.04	4.22	4.11	2.64	0.35
Other Current Assets	15.17	11.51	19.19	13.4	8.56	6.58
Total Current Assets	198.37	233.92	350.16	275.61	276.53	278.57
Property, Plant & Equipment	4.45	4.88	7.38	9.56	11.58	13.66
Long-Term Investments	0	0	0	0	24.22	2.02
Other Long-Term Assets	1.64	1.64	0.63	20.14	0.72	0.71
Total Long-Term Assets	6.09	6.52	8.01	29.7	36.52	16.39
Total Assets	204.46	240.44	358.17	305.31	313.05	294.96
Accounts Payable	5.03	3.12	2.77	1.6	4.45	0.99
Deferred Revenue	0	0	0	0	0.3	4.53
Current Debt	3.43	3.31	2.87	2.32	1.92	1.65
Other Current Liabilities	56.89	63.05	60.26	69.8	53.54	39.19
Total Current Liabilities	65.34	69.48	65.91	73.72	60.2	46.35
Long-Term Debt	173.01	173.71	176.2	178.26	129.21	123.06
Other Long-Term Liabilities	135.06	133.46	132.72	133	73.09	75.78
Total Long-Term Liabilities	308.07	307.17	308.92	311.26	202.3	198.84
Total Liabilities	373.41	376.64	374.83	384.98	262.5	245.19
Total Debt	176.44	177.02	179.07	180.58	131.13	124.71
Debt Growth	-1.21%	-1.15%	-0.83%	37.71%	5.15%	21.47%
Retained Earnings	-1,524.4	-1,487.04	-1,343.94	-1,178.65	-1,069.61	-873.34
Comprehensive Income	-0.52	-0.16	-0.64	0.19	0.52	-0.04
Shareholders' Equity	-168.96	-136.21	-16.66	-79.67	50.55	49.77
Net Cash / Debt	-27.1	15.39	100.59	55.02	121.31	139.08
Net Cash / Debt Growth	-	-84.70%	82.81%	-54.64%	-12.78%	-38.53%
Net Cash Per Share	-0.23	0.13	1.23	0.73	1.68	2.24
Working Capital	133.03	164.44	284.25	201.89	216.33	232.22
Book Value Per Share	-1.46	-1.19	-0.20	-1.06	0.70	0.80

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).